Overview

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Status:
Completed
Trial end date:
2014-09-15
Target enrollment:
Participant gender:
Summary
To provide open-label re-treatment with PROCHYMAL to subjects enrolled in companion Protocol 603 to evaluate the safety in subjects with active Crohn's disease who are resistant to standard Crohn's disease therapies.
Phase:
Phase 3
Details
Lead Sponsor:
Mesoblast International Sàrl
Mesoblast, Inc.
Treatments:
Remestemcel-l